Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B4TN
|
|||
| Former ID |
DAP001125
|
|||
| Drug Name |
Biperiden
|
|||
| Synonyms |
Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F06] | Approved | [1] | |
| Therapeutic Class |
Antiparkinson Agents
|
|||
| Company |
Knoll Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H29NO
|
|||
| Canonical SMILES |
C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
|
|||
| InChI |
1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
|
|||
| InChIKey |
YSXKPIUOCJLQIE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 514-65-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10143, 5493029, 7847844, 8151597, 10524841, 11456991, 11466530, 11467650, 11486080, 14752229, 29221547, 46508325, 47275123, 47720190, 48317976, 50017052, 53788571, 57321294, 76693621, 85209894, 90341640, 92308107, 92729934, 103024637, 103304259, 104098413, 104300422, 124894170, 124894171, 126688938, 129843440, 134338370, 134978790, 137248602, 143201313, 144075883, 160964152, 163409099, 163847731, 174006780, 175267713, 175611146, 178103704, 179225300, 206246485, 210274830, 210280462, 223672012, 223889014, 226421316
|
|||
| ChEBI ID |
CHEBI:3112
|
|||
| ADReCS Drug ID | BADD_D00275 | |||
| SuperDrug ATC ID |
N04AA02
|
|||
| SuperDrug CAS ID |
cas=000514658
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Biperiden can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.488; p = 0.047). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Biperiden can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.583; p = 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Biperiden can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.385; p = 0.045). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Biperiden can be metabolized by Clostridium sp. (log2FC = -0.361; p = 0.047). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.